Company Event on Friday, September 4th 2009!

BRAHMS KRYPTOR compact is certified by the Fetal Medicine Foundation (FMF)

Hennigsdorf, Germany, 16-07-2009. The Fetal Medicine Foundation (FMF) confirmed that BRAHMS KRYPTOR compact is fulfilling the requirements for first trimester biochemical screening.

New Cardiac Marker Copeptin accelerates Diagnosis of Acute Myocardial Infarction (AMI)

Hennigsdorf, July 2, 2009. The novel biomarker Copeptin can improve patient management in the Emergency Department (ED). The study “Incremental Value of Copeptin for Rapid Rule Out of Acute Myocardial Infarction (AMI)” was recently published in the Journal of the American College of Cardiology (JACC).

B·R·A·H·M·S Iberia S.L. starts business operations

B·R·A·H·M·S Aktiengesellschaft is pleased to announce the incorporation of its Spanish affiliate denominated B·R·A·H·M·S Iberia S.L.

LANCIO SUL MERCATO DI UN NUOVO PRODOTTO PER SCREENING PRENATALE: Software B·R·A·H·M·S Fast Screen pre II

Siamo orgogliosi di annunciare il lancio di un nuovo prodotto B·R·A·H·M·S a marchio CE. B·R·A·H·M·S Fast Screen pre II è un software per calcolare il rischio individuale per la Sindrome di Down (trisomia 21), la Sindrome di Edward (trisomia 18) e i difetti del tubo neurale (NTD) del feto nel secondo trimestre di gravidanza (epoca gestazionale fra 14+0 e 19+6).

B·R·A·H·M·S Announces New Blood Test Better Predicts Heart Failure Outcomes in Emergency Setting

Data Presented in a Late Breaker Presentation at AHA Shows MR-proADM Surpasses Industry Standard

New biomarkers: Substantial success in the improvement of diagnosis of patients suffering from shortness of breath

BACH study shows that MR-proANP adds additional information on standard of care in the diagnosis of acute congestive heart failure. The use of PCT together with MR-proANP supports the differential diagnosis of pneumonia and congestive heart failure.

B·R·A·H·M·S AKTIENGESELLSCHAFT e DIASORIN S.P.A. hanno stipulato un nuovo accordo di licenza relativo al TEST DELLA PROCALCITONINA (PCT)

B·R·A·H·M·S AKTIENGESELLSCHAFT e DIASORIN S.P.A. hanno stipulato un nuovo accordo di licenza relativo al TEST DELLA PROCALCITONINA (PCT) per le PIATTAFORME PER IMMUNODIAGNOSTICA LIAISON di DIASORIN